ENTA Insider Trading Activity and SEC Form 4 Filings
ENTA insider trading summary
Over the past 12 months, insiders at Enanta Pharmaceuticals Inc (ENTA) reported 9 sales worth $183K by 7 insiders and no open-market purchases on SEC Form 4. Net insider selling was $183K.
Latest ENTA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 5, 2025 | Yat Sun Or | Chief Scientific Officer | Sell | $34K (2,390 @ $14.23) |
| Dec 5, 2025 | Harry R. Trout III | See Remarks | Sell | $8K (542 @ $14.23) |
| Dec 5, 2025 | Tara Lynn Kieffer | Chief Product Strategy Officer | Sell | $30K (2,106 @ $14.23) |
| Dec 5, 2025 | Scott T. Rottinghaus | Chief Medical Officer | Sell | $11K (798 @ $14.23) |
| Dec 5, 2025 | Jay R. Luly | President and CEO | Sell | $67K (4,743 @ $14.23) |
| Dec 5, 2025 | Brendan Luu | Chief Business Officer | Sell | $20K (1,394 @ $14.23) |
| Dec 5, 2025 | Kathleen S. Capps | See Remarks | Sell | $5K (323 @ $14.23) |
| Dec 2, 2025 | Kathleen S. Capps | See Remarks | Sell | $3K (207 @ $13.96) |
| Dec 2, 2025 | Harry R. Trout III | See Remarks | Sell | $5K (380 @ $13.96) |
| Feb 12, 2025 | Jay R. Luly | President and CEO | Buy | $256K (45,000 @ $5.69) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.